Individuals residing with ocular hypertension are at a big danger of growing major open-angle glaucoma (POAG), which progressively damages the optic nerve.1 However nicotinamide presents some promise. In a cohort examine just lately printed in JAMA Ophthalmology, a crew led by Jawad Muayad, MD, investigated whether or not nicotinamide supplementation reduces the danger of major open-angle glaucoma in sufferers with raised ocular strain and delays the necessity for medical or surgical intervention.
The researchers pooled deidentified digital medical report knowledge from a analysis community of 67 US healthcare firms over 20 years, from March 2006 via March 2026.
They noticed sufferers who had been identified with ocular hypertension and had acquired at the least one healthcare go to. They didn’t embody any sufferers who had open-angle glaucoma, had acquired laser eye surgical procedure, or have been receiving any remedy to cut back eye strain.
Propensity rating matching was used to create two teams of 1,460 sufferers, controlling for age, intercourse, and baseline well being. The publicity group acquired documented nicotinamide supplementation, however the management group didn’t.
The common age of members within the publicity group was 54.4 years, with 57.9% being feminine. The common age within the management group was 54.9 years, with females making up 59.5%.
The findings from the examine revealed that nicotinamide supplementation lowered the danger of development to glaucoma by two-thirds.
Within the management group, 9.0% acquired a proper glaucoma prognosis, in contrast with solely 3.5% within the publicity group (hazard ratio [HR], 0.34; 95% CI, 0.25-0.47; P<0.001).
Individuals within the publicity group additionally confirmed 43% much less danger of requiring day by day eye drops. (HR, 0.57; 95% CI, 0.48-0.68; P<0.001). Within the management group, 21.2% of sufferers (309 folks) required eye drop remedy, in contrast with 13.6% within the nicotinamide group (198 folks).
Nicotinamide supplementation additionally lowered the danger of requiring surgical procedure by 62%. (HR, 0.38; 95% CI, 0.19-0.74; P=0.003). Within the management group, 1.9% of individuals finally required surgical procedure towards 0.8% within the nicotinamide group.
By merely introducing a vitamin complement, the danger of ocular hypertension progressing to POAG may be lowered considerably. This discovering represents a scientific progress that advantages each sufferers and clinicians. “By probably delaying POAG prognosis and lowering the speed of subsequent prescribed interventions, nicotinamide represents a possible adjunctive technique complementary to plain remedy,” stated the authors. Additional investigation is required to find out whether or not nicotinamide may be included into routine ocular hypertension care.
